For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback